^
Association details:
Biomarker:SOX10 underexpression
Cancer:Melanoma
Drug Class:BRAF inhibitor +
MEK inhibitor
Direction:Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
Source:
Title:

40 - Targeting SOX10-deficient cells to reduce resistance to targeted therapy in melanoma

Published date:
03/10/2021
Excerpt:
...melanoma models...cell lines generated from xenograft tumors that have acquired resistance to either vemurafenib, paradox-breaking BRAFi or the combination of BRAFi + MEKi showed dramatically reduced SOX10 expression compared to their parental counterparts.